International Journal of Microbiology

International Journal of Microbiology / 2010 / Article

Research Article | Open Access

Volume 2010 |Article ID 654858 |

James Price, Gillian Baker, Ian Heath, Karen Walker-Bone, Marc Cubbon, Sally Curtis, Mark C. Enright, Jodi Lindsay, John Paul, Martin Llewelyn, "Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia", International Journal of Microbiology, vol. 2010, Article ID 654858, 7 pages, 2010.

Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia

Academic Editor: Michael M. Tunney
Received05 Nov 2009
Accepted08 Feb 2010
Published16 Mar 2010


Staphylococcus aureus bacteraemia (SAB) is commonly complicated by metastatic infection or relapse after treatment. Objectives. The study aim was to determine the role of bacterial, host, and management factors in development of complicated SAB. Methods. A prospectively-conducted observational study gathered data on predisposition, management and outcome of 100 consecutive SAB cases. Antibiotic susceptibilities and genetic lineage of bacterial isolates were determined. Further clinical and microbiological data were gathered on two retrospective series from 1999–2000 ( ) and 2004 ( ). Results. In the prospective cases, 27% met our definition of complicated disease. Expressed as RR and 95% CI, complicated disease was associated with diabetes (1.58, 1.00–2.48), injecting-drug use (5.48, 0.88–33.49), community-onset of symptoms (1.4, 1.02–1.92), and symptom duration hours prior to starting effective antibiotic therapy (2.10, 1.22–3.61). Uncomplicated disease was associated with the presence of a central line (0.69, 0.55–0.88) and prompt removal of a primary focus (0.71, 0.57–0.90). Neither methicillin resistance nor genetic lineage was associated with complicated disease, but methicillin resistance was associated with higher mortality. Conclusions. This study demonstrates that clinical rather than microbial factors are the major determinants of SAB outcome and underscores the importance of early treatment.

1. Introduction

Staphylococcus aureus bacteraemia (SAB) is one of the commonest forms of healthcare associated infection. Among causes of bacteraemia, S. aureus is notable for how commonly it is complicated by the development of secondary foci of infection and relapse. Reported rates of complicated disease range from 12.5% to 53% depending on case definition and the population studied [14]. Clinical risk factors for development of complicated bacteraemia are well defined and include community onset of disease and suboptimal medical management [3, 5]. Few data exist on the importance of microbial factors, other than methicillin resistance, in determining the outcome of S. aureus infection. Previous studies have compared strain genotype from invasive and noninvasive disease [6, 7] but we are aware of only one previous study assessing the impact of genotype on outcome of bacteraemia [8]. The aim of this study was to determine the relative impact of clinical and microbiological factors on risk of developing complicated SAB.

2. Methods

Brighton and Sussex University Hospitals NHS Trust (BSUH) is an 820-bed Teaching Hospital with a high SAB rate. A prospectively conducted observational study of all new cases of SAB was conducted at BSUH between August 2006 and May 2007. The sampling time-frame was determined by the tenure of the trainee microbiologist running the study. Anonymised clinical data were gathered from the case notes on the day of the first clinical review and at a follow-up by the infectious diseases team.

A retrospective evaluation was also performed of two cohorts of consecutive SAB cases from which isolates had been archived as part of a previous unpublished study. The first consisted of SAB episodes during 1999-2000. The second consisted of SAB episodes between January and May 2004. Clinical data were collated from case notes and laboratory and administrative databases.

3. Ethics Statement

The study was approved by the Brighton and Sussex University Hospital NHS Trust Research and Development office as a service evaluation gathering anonymised, routine clinical data from patient records and not requiring formal ethical review.

4. Case Definitions

SAB was defined as at least one positive blood culture for S. aureus. A primary focus of infection was defined as the likely source of the bacteraemia according to clinician assessment. Complicated bacteraemia was defined as the development of either a secondary deep focus of infection (on the basis of clinical or microbiological evidence) or relapse of bacteraemia (a second episode of SAB within three months of the first episode). SAB was considered to be community-associated using the CDC definition (diagnosis 48 hours of admission, no previous admission to hospital within twelve months, no previous MRSA positive cultures, and no long-term indwelling devices) [9]. Community-onset disease was defined as SAB diagnosed within 48hrs of admission but not fulfilling criteria for community-associated disease. All SAB diagnosed after 48hrs of admission was defined as hospital onset. Initial antibiotic management was defined as having been “effective” if the patient received parenteral therapy with a beta-lactam antibiotic or a glycopeptide (depending on sensitivities) either alone or in combination with other agents.

5. Microbiological Analysis

Blood culture isolates were identified as S. aureus on the basis of colony morphology, Gram’s staining, and a positive coagulase test. Antibiotic susceptibility was performed by disk diffusion analysis according to British Society for Antimicrobial Chemotherapy guidelines and vancomycin minimum inhibitory concentrations (MIC) were determined by E-test.

Bacterial isolates from the prospective study were genotyped using a restriction-modification (RM) test. This assigns S. aureus isolates to six of the ten major S. aureus lineages, clonal complex (CC) 1, 5, 8, 22 (corresponding to MLST 22, predominantly EMRSA-15), 30 (corresponding to MLST 30 and 36, predominantly EMRSA-16), and 45 (corresponding to MLST 45, 4, and 54) [10, 11]. Briefly, RM typing exploits the close relationship between variations in the two hsdS genes and S. aureus lineage. Combinations of eight primers are used in three PCR reactions to produce products of different sizes [11]. Genes encoding Panton-Valentine Leukocidin (PVL), Toxic Shock Syndrome Toxin (tst), and enterotoxins (sea and sej) were sought by PCR using published primers [1214].

6. Statistical Analysis

Data were analysed using SPSS 15.0.0 and Minitab 15. Associations between complicated disease and the variables described were univariately assessed using the Fisher’s exact test for proportions and the Mann-Whitney U test for nonparametric continuous variables. Probability values 0.05 were considered significant. For categorical variables the relative risk (RR) and 95% CI were calculated. Variables statistically significant in the univariate analysis were analysed in a multivariate logistic regression model to assess which were the significant predictors of complicated disease.

7. Results

One hundred SAB cases occurred during the study period. Fifty-two (52%) were MRSA, equating to an overall rate of 6.68 SAB cases and 3.47 MRSA cases per/10 000 bed days. The national average MRSA bacteraemia rate for acute trusts at the start of the study period was 1.77/10 000 bed days

8. Patient Characteristics and Clinical Management

Fifty-nine (59%) of SAB cases were male and the median age was 65.5 years. Twenty-seven (27%) fulfilled the criteria for complicated SAB (Table 1); 24 (24%) had secondary site infections, 6 (6%) had relapse and 3 had both. On univariate analysis, complicated bacteraemia was associated with community-onset disease (RR = 1.4, 95% CI: 1.02–1.92, ), diabetes mellitus (RR = 1.58, 95% CI: 1.00–2.48, ), and injecting drug use (IDU) (RR = 5.48, 95% CI: 0.88–33.49, ). The presence of a central line was associated with a reduced risk of complicated disease (RR = 0.69, 95% CI: 0.55–0.88 ).

Clinical CharacteristicsTotalUncomplicatedComplicatedRR95% CI

  (with IQR)(46–78)(42–77)(49–78)

Male Gender59 (%)40 (54.8%)19 (70.4%)1.280.94–1.50.096

Patient Location
 Admission Unit27(%)14 (19.2%)13 (48.1%)1.561.07–2.28.006
 ICU11(%)10 (13.7%)1 (3.7%)0.780.62–0.98.280
 Renal Unit19(%)16 (21.9%)3 (11.1%)0.840.66–1.06.265
 Medical Wards30(%)25 (34.2%)5 (18.5%)0.820.65–1.03.148
 Surgical Wards13(%)8 (10.9%)5 (18.5%)1.210.78–1.90.329

 Community Acquired7(%)4 (5.5%)3 (11.1%)1.300.68–2.49.384

 Community Onset33(%)19 (26.0%)14 (51.9%)1.401.021.92.018

 Diabetes Mellitus20(%)10 (13.7%)10 (37.3%)1.581.002.48.021
 IDU7(%)1 (1.4%)6 (22.2%)5.420.8833.49.001
 Smoker22(%)13 (17.8%)9 (33.3%)1.300.90–1.88.109
 Excess Alcohol11(%)9 (12.3%)2 (7.4%)0.880.65–1.20.722
 Haemodialysis17(%)14 (19.2%)3 (11.1%)0.860.67–1.12.55
 Central line in situ43(%)38 (52%)5 (18.5%)0.690.55–0.88.003
 Recent Antibiotics26(%)21 (28.8%)5 (18.5%)0.870.69–1.11.442
 Recent Steroid Therapy12(%)9 (12.3%)3 (11.1%)0.970.68–1.381.000
 Recent Immunosuppression6(%)4 (5.5%)2 (7.4%)1.100.62–1.96.660

Primary Focus Removed
72 hours41(%)36 (49.3%)5 (18.5%)0.710.57–0.90.006
72 hours/not removed36(%)22 (30.1%)14 (51.8%)1.300.98–1.74.061
 Not identified23(%)15 (20.5%)8 (29.6%)1.160.83–1.60.423
Initiation of effective antibiotics ≥ 48 hours32 (%)18 (24.7%)14 (51.9%)2.101.22–3.61.015
Duration of IV treatment 2 weeks66(%)47 (64.4%)19 (70.4%)1.070.84–1.37.641

Mortality (all cause at 30 days)38/97**24/73 (32.9%)14/25** (56%)1.290.99–1.70.057

P-value adjusted for ties. **two patients with complicated bacteraemia were lost to follow up at 30 days.

In 77% of cases a primary source of bacteraemia was apparent. Although the presence or absence of a primary source did not correlate with complicated disease, removal of an identified focus within 72 hours was associated with a lower risk of complicated disease than when the focus was removed beyond this time or not removed at all (RR = 0.71, 95% CI: 0.57–0.90, ). Bacteraemic patients who were symptomatic for 48 hours before effective antibiotic therapy was started were at higher risk of complicated disease (RR = 2.10, 95% CI: 1.22–3.61, ). There was no relationship between duration of effective intravenous therapy 2 weeks and complicated disease (RR = 1.07, 95% CI: 0.84–1.37, ). The risk of death in patients with complicated disease was higher (RR = 1.29, 95% CI: 0.99–1.70, ).

In the multivariate analysis, both forward and backward likelihood ratio (LR) approaches selected diabetes mellitus, IDU and Time to Removal of Primary Focus in their final model, where backward LR also included time to initiation of effective antibiotics. Diabetes mellitus and IDU were significant at the 5% level for both approaches with P-values in the backward LR model of.005 and.004, respectively.

9. Retrospective Study

The two retrospective case series comprised 57 bacteraemias in 57 patients in 1999-2000 and 116 bacteraemias in 114 patients in 2004 (Table 2). Good quality basic demographic and microbiological data were available on the great majority of cases but full case notes were available for only 22/57 (38.6%) and 73/116 (62.9%), respectively. The rate of complicated disease among evaluable patients in the 2004 series (20/73 (27.4%)) was comparable with that found in the prospective series and higher than that found in the 1999-2000 series (2/22 (9.1%)) but this did not reach statistical significance ( ). There was a trend towards more diabetes mellitus and intravenous drug use in the 2004 series compared with the 1999-2000 series, 27.4% versus 9.1% ( ) 9.6% versus 0% ( ), respectively.

Clinical Characteristics1999-2000 series2004 series

 Median (interquartile range)*63.1 (53–78)68.85 (52–80).23

Male Gender38 (66.7%)81 (69.8%).4

Patient location
 Admission unit8/47 (17.0%)18/112 (16.1%).53
 ICU8/47 (17.0%)19/112 (16.9%).58
 Renal unit8/47 (17.0%)26/112 (23.2%).26
 Medical wards17/47 (36.2%)32/112 (28.6%).22
 Surgical wards6/47 (12.8%)17/112 (15.2%).45

Community acquired2/22 (9.1%)4/73 (5.5%).42

Community onset5/22 (22.7%)21/73 (28.7%).39

Diabetes Mellitus2/22 (9%)20/73 (27.4%).06

IDU0/22 (0%)7/73 (9.6%).15

Smoker6/22 (27.3%)19/73 (26.0%).55

Central line in situ 10/22 (45.5%)39/73 (53.4%).3

10. Microbial Analysis

Data on antibiotic sensitivity of the S. aureus isolates were available on all isolates from the clinical records. The number of bacteraemias caused by MRSA was 30 (52.6%) in 1999, 69 (59.5%) in 2004, and 52 (52%) in 2006. Forty-five of patients received vancomycin as treatment for their SAB. These isolates were all confirmed as vancomycin sensitive with vancomycin MIC by E-test ranging between 0.75 and 2.0  g/mL.

Although all 57 isolates for the 1999-2000 series had been typed, only 36 could be recovered from archives of the 2004 series. From the 100 episodes of bacteraemia in 2006, two MRSA and one MSSA isolate were not saved, allowing 97 isolates to be typed. No significant changes in the lineages of S. aureus causing bacteraemia occurred between 1999 and 2006, although the proportion of MRSA bacteraemias caused by CC30 (E-MRSA16) increased progressively from 36.6% to 54%, while the contribution of CC22 (E-MRSA15) decreased from 50% to 38% (Table 3).

Clonal ComplexMSSAMRSA


comprising MLSTs 6, 12(x2) 15, 123(x2), and 188, comprising MLSTs 12, 15, 20, 97, 101, and 123, not MLSTed. **comprising MLST12 (x3). CC=clonal complex.

Combining data from the retrospective and prospective series yielded a total of 195 episodes of bacteraemia for which outcome and antibiotic resistance data were available. Of these, 109 (55.6%) were MRSA bacteraemias, and 49 (25.1%) were complicated cases. Methicillin resistance was not associated with complicated disease (25.7% vs. 24.4%, ) but was associated with excess mortality (46.8% vs. 30.2%, ). MRSA bacteraemia was associated with a significant excess of diabetic patients (30.1% vs. 8.3%, ) and inappropriate initial antibiotic treatment (40.3% vs. 10.4%, ).

For 152 cases full clinical and typing data were available. These data show no association between methicillin resistance or staphylococcal lineage and complicated bacteraemia (Table 4).

Clonal complexTotalUncomplicatedComplicatedRR95% CI
(76.3%) (23.7%)

CC305342 (79.2%)11 (20.8%)0.940.79–1.130.689
CC223929 (74.4%)10 (25.6%)1.040.84–1.280.828
CC451511 (73.3%)4 (26.7%)1.050.76–1.440.755
CC1117 (63.6)4 (36.4%)1.220.77–1.920.291
CC876 (85.7%)1 (14.3%)0.880.65–1.211.00
CC576 (85.7%)1 (14.3%)0.880.65–1.211.00
Other2015 (75%)5 (25%)1.020.78–1.341.00

Toxin genotyping demonstrated that 3/188 were PVL positive (1.6%) and other gene frequencies were: tst 83/188 (44.1%), sea 66/188 (35%), and sej 4/188 (2.1%). There were no differences in the frequency of these toxin genes between the three time-series. There was no relationship between toxin genotype and complicated disease or mortality at three months. However, all CC30 strains were tst positive and all four sej positive isolates were of CC5 (Table 5).

Clonal ComplexToxin Gene
PVL tst-1 sej sea


11. Discussion

The importance of patient and management factors in determining outcome of S. aureus bacteraemia is well established [3, 5]. However, while a wide range of bacterial toxin and virulence factors is variably present in S. aureus [15] the relationship between strain variation and outcome of S. aureus infection is not clear. Peacock et al. reported an association between seven variable toxin and adhesion genes and invasive disease [6], while Lindsay et al. found no association between putative virulence genes and invasive disease using a microarray approach [7]. Fowler et al. studied 324 patients with catheter-related SAB and identified methicillin resistance and the presence of sea as risk factors for complicated disease [8]. Lalani et al. evaluated the relationship between bacterial genotype and outcome of 230 episodes of SAB in a phase III clinical trial [16]. In addition to geographical differences in distribution of putative virulence factors, relationships between lineage and clinical presentation were identified. In this study persistence of MRSA bacteraemia after treatment was associated with seg and negatively associated with PVL. Ganga et al. found a relationship between SCCmec type and outcome in a study of 253 episodes of SAB, with SCCmec II being an independent predictor of mortality and SCCmec IVa of metastatic infection [17].

The population structure of human S. aureus comprises 10 major lineages, or clonal complexes, which have evolved independently [7]. Exchange of genetic material between lineages occurs infrequently, probably because of restriction modification systems [18]. Consequently, if strain differences are important in determining whether bacteraemia is complicated by secondary sites of infection or relapse, then this is likely to be apparent as an association with lineage. However, in our study of 152 cases of SAB we have found no evidence of a relationship between lineage and the development of complicated disease. Nor did we find any association between complicated disease and the presence of PVL, tst, sea, or sej toxin genes. The presence of tst gene was strongly related to CC30 (EMRSA-16) which is consistent with previous studies [6, 7, 19]. However in contrast to the findings of Holtfreter et al. who identified 93.3% of sej gene positive bacteraemic strains in CC8 complex and 6.7% in CC45, we have found sej only in CC5 [19]. Our results uphold their hypothesis that superantigen genes have a strong association to clonal complex, and the most likely explanation for the lineage-specific differences relates to geographical variation.

In contrast with Fowler’s study [8] we have found no relationship between complicated disease and methicillin resistance. But, in keeping with previous studies recently subjected to meta-analysis, we have found methicillin resistance to be associated with excess mortality [20]. This is likely to be related to higher rates of comorbid disease in these patients, but could also be due to the increased failure rate of MRSA therapy compared to MSSA [20].

Reported figures for the rate at which SAB is complicated by metastatic infection or relapse vary widely between studies. Fowler et al. reported a relapse rate of 12.7% and a metastatic infection rate of 30.3% in North Carolina [2]. In contrast, the UK experience of SAB has consistently been that complicated disease is less common. Among 147 cases from Birmingham, Das et al. reported relapse and metastatic infection rates of 6.5% and 7% [21]. Among 815 cases from Essex, Melzer et al. found a metastatic infection rate of 6.6% [22]. In our study, rates varied over time. Among the patients in the 1999-2000 series for whom we were able to get fully evaluable outcome data, the rate of complicated disease was only 9.1% compared with 27.4% and 27.0% in the 2004 and 2006 series, respectively. This difference is likely related to the small number of diabetics and IDUs in the 1999-2000 series which could reflect genuine differences in the clinical work-load at the trust but should be interpreted with caution since only a small proportion of cases were evaluable. Another potential explanation would have been the emergence of a new virulent clone of S. aureus over time but comparison of the lineages from 1999, 2004 and 2006 indicates that no new strain emerged, but that there was a gradual increase of EMRSA-16 (CC30).

Previous studies have reported increases in vancomycin MIC to be associated with treatment failure in SAB [23] however we have found no evidence of raised vancomycin MIC. Indeed we have previously reported an apparently paradoxical relationship between the clinical outcome of SAB and the MIC of vancomycin in these patients [24].

Our study has a number of important limitations. It is relatively small and from a single centre and thus does not have the power to detect modest associations between bacterial lineage and outcome. By being observational, patients were not subject to a standardised approach of diagnosis and treatment. For example only 43% of subjects had an echocardiogram and since follow-up blood cultures are rarely performed at our institution in the management of SAB we were unable to assess persistence of bacteraemia on treatment. For these reasons, we may have underestimated the number of complicated cases. However, the role of echocardiography in cases of SAB considered to be at low risk of endocarditis is controversial [25] and having followed-up each case for three months, we feel we are unlikely to have misclassified any complicated cases. In looking at the role of genotype we have combined our robust prospectively gathered data with the less complete retrospectively gathered data set. While being not ideal this has allowed us to more confidently exclude a major role for bacterial genotype in determining outcome and is unlikely to have introduced any significant element of bias. We have classified any second episode of SAB within three months as a relapse rather than considering the possibility of reinfection with a different strain. While this could reduce the power of our study to detect an impact of genotype on outcome, the number of relapses was small so this is also unlikely to be a significant effect.

The major strength of our study is that it places the role of bacterial genotype in the context of clinical factors. In contrast with the findings of Fowler and Lalani we have not found a relationship between genotype and outcome [8, 16]. It is likely this reflects differences in patient selection, geographical differences and sample size. Our failure to find evidence of a relationship between bacterial genetic factors and bacteraemia outcome in the 152 cases we have analysed demonstrates that any impact of microbial factors is likely to be small compared to the impact of host and management factors.

The associations we have found, duration of symptoms prior to adequate antibiotic therapy, delay in removal of a source of bacteraemia and community onset of symptoms indicate that duration of bacteraemia is the central determinant of risk of complicated disease. Patients who have community onset of symptoms, including IDUs are likely to present later than hospitalised patients. Injecting drug use and diabetes have been identified by some previous studies as risk factors for mortality from SAB [2628]. The only study we are aware of looking specifically on the impact of diabetes on SAB found an increased rate of endocarditis compared with nondiabetic patients but no difference in mortality [29].

In summary, we have confirmed the previously described risk factors for complicated SAB; community onset of symptoms, diabetes mellitus, delay in initiation of effective antibiotics and failure to identify and remove a primary focus of infection and failed to identify any role for bacterial genotype. Our findings underscore the importance of clinical assessment of patients with SAB for risk of complicated disease and indicate that clinical rather than bacterial factors are the major determinants of outcome in this disease.


The authors thank Dr Amanda Winn for assistance with the statistical analysis. This research was funded by the Hospital Infection Society.


  1. S. Lautenschlager, C. Herzog, and W. Zimmerli, “Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions,” Clinical Infectious Diseases, vol. 16, no. 4, pp. 567–573, 1993. View at: Google Scholar
  2. V. G. Fowler Jr., L. L. Sanders, D. J. Sexton et al., “Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients,” Clinical Infectious Diseases, vol. 27, no. 3, pp. 478–486, 1998. View at: Google Scholar
  3. V. G. Fowler Jr., M. K. Olsen, G. R. Corey et al., “Clinical identifiers of complicated Staphylococcus aureus bacteremia,” Archives of Internal Medicine, vol. 163, no. 17, pp. 2066–2072, 2003. View at: Publisher Site | Google Scholar
  4. H. Ringberg, A. Thorén, and B. Lilja, “Metastatic complications of Staphylococcus aureus septicemia. To seek is to find,” Infection, vol. 28, no. 3, pp. 132–136, 2000. View at: Publisher Site | Google Scholar
  5. F.-Y. Chang, J. E. Peacock Jr., D. M. Musher et al., “Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study,” Medicine, vol. 82, no. 5, pp. 333–339, 2003. View at: Publisher Site | Google Scholar
  6. S. J. Peacock, C. E. Moore, A. Justice et al., “Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus,” Infection and Immunity, vol. 70, no. 9, pp. 4987–4996, 2002. View at: Publisher Site | Google Scholar
  7. J. A. Lindsay, C. E. Moore, N. P. Day et al., “Microarrays reveal that each of the ten dominant lineages of Staphylococcus aureus has a unique combination of surface-associated and regulatory genes,” Journal of Bacteriology, vol. 188, no. 2, pp. 669–676, 2006. View at: Publisher Site | Google Scholar
  8. V. G. Fowler Jr., A. Justice, C. Moore et al., “Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia,” Clinical Infectious Diseases, vol. 40, no. 5, pp. 695–703, 2005. View at: Publisher Site | Google Scholar
  9. R. M. Klevens, M. A. Morrison, J. Nadle et al., “Invasive methicillin-resistant Staphylococcus aureus infections in the United States,” Journal of the American Medical Association, vol. 298, no. 15, pp. 1763–1771, 2007. View at: Publisher Site | Google Scholar
  10. E. J. Feil, J. E. Cooper, H. Grundmann et al., “How clonal is Staphylococcus aureus?” Journal of Bacteriology, vol. 185, no. 11, pp. 3307–3316, 2003. View at: Publisher Site | Google Scholar
  11. J. D. Cockfield, S. Pathak, J. D. Edgeworth, and J. A. Lindsay, “Rapid determination of hospital-acquired meticillin-resistant Staphylococcus aureus lineages,” Journal of Medical Microbiology, vol. 56, no. 5, pp. 614–619, 2007. View at: Publisher Site | Google Scholar
  12. S. Jarraud, C. Mougel, J. Thioulouse et al., “Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease,” Infection and Immunity, vol. 70, no. 2, pp. 631–641, 2002. View at: Publisher Site | Google Scholar
  13. K. Becker, R. Roth, and G. Peters, “Rapid and specific detection of toxigenic Staphylococcus aureus: use of two multiplex PCR enzyme immunoassays for amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin genes, and toxic shock syndrome toxin 1 gene,” Journal of Clinical Microbiology, vol. 36, no. 9, pp. 2548–2553, 1998. View at: Google Scholar
  14. H.-Y. Tsen and T.-R. Chen, “Use of the polymerase chain reaction for specific detection of type A, D and E enterotoxigenic Staphylococcus aureus in foods,” Applied Microbiology and Biotechnology, vol. 37, no. 5, pp. 685–690, 1992. View at: Google Scholar
  15. R. J. Gordon and F. D. Lowy, “Pathogenesis of methicillin-resistant Staphylococcus aureus infection,” Clinical Infectious Diseases, vol. 46, supplement 5, pp. S350–S359, 2008. View at: Publisher Site | Google Scholar
  16. T. Lalani, J. J. Federspiel, H. W. Boucher et al., “Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients,” Journal of Clinical Microbiology, vol. 46, no. 9, pp. 2890–2896, 2008. View at: Publisher Site | Google Scholar
  17. R. Ganga, K. Riederer, M. Sharma et al., “Role of SCCmec type in outcome of Staphylococcus aureus bacteremia in a single medical center,” Journal of Clinical Microbiology, vol. 47, no. 3, pp. 590–595, 2009. View at: Publisher Site | Google Scholar
  18. D. E. Waldron and J. A. Lindsay, “Sau1: a novel lineage-specific type I restriction-modification system that blocks horizontal gene transfer into Staphylococcus aureus and between S. aureus isolates of different lineages,” Journal of Bacteriology, vol. 188, no. 15, pp. 5578–5585, 2006. View at: Publisher Site | Google Scholar
  19. S. Holtfreter, D. Grumann, M. Schmudde et al., “Clonal distribution of superantigen genes in clinical Staphylococcus aureus isolates,” Journal of Clinical Microbiology, vol. 45, no. 8, pp. 2669–2680, 2007. View at: Publisher Site | Google Scholar
  20. M. H. Kollef, “Limitations of vancomycin in the management of resistant staphylococcal infections,” Clinical Infectious Diseases, vol. 45, supplement 3, pp. S191–S195, 2007. View at: Publisher Site | Google Scholar
  21. I. Das, N. O'Connell, and P. Lambert, “Epidemiology, clinical and laboratory characteristics of Staphylococcus aureus bacteraemia in a university hospital in UK,” Journal of Hospital Infection, vol. 65, no. 2, pp. 117–123, 2007. View at: Publisher Site | Google Scholar
  22. M. Melzer, S. J. Eykyn, W. R. Gransden, and S. Chinn, “Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia,” Clinical Infectious Diseases, vol. 37, no. 11, pp. 1453–1460, 2003. View at: Publisher Site | Google Scholar
  23. A. Soriano, F. Marco, J. A. Martinez et al., “Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia,” Clinical Infectious Diseases, vol. 46, no. 2, pp. 193–200, 2008. View at: Publisher Site | Google Scholar
  24. J. Price, S. Atkinson, M. Llewelyn, and J. Paul, “Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin,” Clinical Infectious Diseases, vol. 48, no. 7, pp. 997–998, 2009. View at: Publisher Site | Google Scholar
  25. A. L. Sullenberger, L. S. Avedissian, and S. M. Kent, “Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia,” Journal of Heart Valve Disease, vol. 14, no. 1, pp. 23–28, 2005. View at: Google Scholar
  26. P. C. Hill, M. Birch, S. Chambers et al., “Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality,” Internal Medicine Journal, vol. 31, no. 2, pp. 97–103, 2001. View at: Publisher Site | Google Scholar
  27. L. E. Wilson, D. L. Thomas, J. Astemborski, T. L. Freedman, and D. Vlahov, “Prospective study of infective endocarditis among injection drug users,” Journal of Infectious Diseases, vol. 185, no. 12, pp. 1761–1766, 2002. View at: Publisher Site | Google Scholar
  28. J. M. Mylotte and A. Tayara, “Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort,” Clinical Infectious Diseases, vol. 31, no. 5, pp. 1170–1174, 2000. View at: Publisher Site | Google Scholar
  29. G. Cooper and R. Platt, “Staphylococcus aureus bacteremia in diabetic patients. Endocarditis and mortality,” American Journal of Medicine, vol. 73, no. 5, pp. 658–662, 1982. View at: Google Scholar

Copyright © 2010 James Price et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.